Mayer Brown announced today the launch of Immuno-Innovation, its newest blog, designed to provide updates on the latest issues at the intersection of Intellectual Property law and immunotherapy by delving into scientific, legal, regulatory and business developments affecting the biopharmaceutical industry. The blog is edited by Lisa Ferri, a co-leader of the firm's global IP practice and the Life Sciences group, and partner Richard McCormick and associate Scott McMurry.
“Recent developments in immunotherapy have transformed the treatment landscape and spurred tremendous investment in this field, leading to a heightened focus on patents as a necessary mechanism to protect innovations,” said Ms. Ferri. “Our goal in launching this blog is to both chronicle and analyze the issues that emerge as the scientific and legal worlds intersect.”
Other members of Mayer Brown’s IP and Life Sciences groups will be regular contributors to the blog, which launches at a particularly relevant and propitious time. “With the emergence of SARS-CoV-2, immunotherapies to combat the virus are front and center. Advances in antibody therapies and vaccines will evolve more rapidly now than ever before, and the consequent effects on patenting and patent disputes are going to have lasting effects in shaping the law," noted Mr. McCormick.
Mayer Brown is uniquely positioned with a full-service global IP practice that is fully integrated with other practices. Taking a multidisciplinary approach to today’s emerging issues in the development, protection and exploitation of intellectual property assets, the firm’s team of IP practitioners provides antitrust guidance on transactions and competition disputes and unsurpassed appellate capabilities before the federal courts, the US Supreme Court and international tribunals.
The firm’s Life Sciences group consists of lawyers from across the firm’s practices with extensive industry knowledge and resources, offering the legal and technical experience and global awareness needed to understand the opportunities offered and challenges presented to the global pharmaceuticals, biotech and medical device industries.
Visit the Immuno-Innovation blog.
“Recent developments in immunotherapy have transformed the treatment landscape and spurred tremendous investment in this field, leading to a heightened focus on patents as a necessary mechanism to protect innovations,” said Ms. Ferri. “Our goal in launching this blog is to both chronicle and analyze the issues that emerge as the scientific and legal worlds intersect.”
Other members of Mayer Brown’s IP and Life Sciences groups will be regular contributors to the blog, which launches at a particularly relevant and propitious time. “With the emergence of SARS-CoV-2, immunotherapies to combat the virus are front and center. Advances in antibody therapies and vaccines will evolve more rapidly now than ever before, and the consequent effects on patenting and patent disputes are going to have lasting effects in shaping the law," noted Mr. McCormick.
Mayer Brown is uniquely positioned with a full-service global IP practice that is fully integrated with other practices. Taking a multidisciplinary approach to today’s emerging issues in the development, protection and exploitation of intellectual property assets, the firm’s team of IP practitioners provides antitrust guidance on transactions and competition disputes and unsurpassed appellate capabilities before the federal courts, the US Supreme Court and international tribunals.
The firm’s Life Sciences group consists of lawyers from across the firm’s practices with extensive industry knowledge and resources, offering the legal and technical experience and global awareness needed to understand the opportunities offered and challenges presented to the global pharmaceuticals, biotech and medical device industries.
Visit the Immuno-Innovation blog.
Contacto
Stay Up To Date With Our Insights
See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe